Liquidia Technologies (LQDA)
(Delayed Data from NSDQ)
$20.31 USD
+0.24 (1.20%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $20.35 +0.04 (0.20%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LQDA 20.31 +0.24(1.20%)
Will LQDA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LQDA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LQDA
Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates
Insmed Stock Jumps 29% on Encouraging PAH Study Results
LQDA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains?
Other News for LQDA
Liquidia Corp (LQDA) Announces Upcoming Second Quarter 2025 Financial Results | LQDA stock news
Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 | LQDA ...
Liquidia (LQDA) Shares Drop Amid Legal Battle with United Therapeutics
United Therapeutics up 7%, Liquidia down 9% in afternoon trading
Bleecker Street Research short United Therapeutics, long Liquidia